Selecting fuchs patients for drug trials involving endothelial cell proliferation

Thomas (Tom) Shearer, Winston Chamberlain, Atsuko Fujii, Mitsuyoshi Azuma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Fuchs endothelial corneal dystrophy (FECD) might be managed by drug treatment before becoming severe enough to require surgery. For a clinical trial of such a drug, we hypothesize that selecting an adequate number of patients with FECD with only moderately compromised cell densities will be challenging. Thus, the purpose of the present study was to measure the prevalence of patients with FECD exhibiting moderately decreased corneal cell densities. Methods: A retrospective data mining study (cross-sectional study) was performed on patient charts presenting at a large US northwestern academic health center by searching for diagnosis ICD-9 code 371.57 and Fuchs corneal dystrophies, including those with prior cataract surgeries and/or existing glaucoma. Patients with prior corneal transplants were excluded. Noncontact specular photomicroscopic data (Topcon 2000) were obtained from the central region whenever possible, and individual eyes were grouped according to cell density (cells/mm2): severe (<800), moderate (800-1,500), and mild (>1,500). Results: The values for 98 eyes from 61 patients with FECD were as follows (mean ± SD): corneal thickness 573 ± 59 μm, cell size 627 ± 336 μm2/cell, coefficient of variation 23 ± 7, and density 1,883 ± 703 cells/mm2. The moderate subgroup with cell density values averaging 1,184 ± 212 (26) comprised 27% of the total FECD patient pool. Conclusions: Only approximately 1 out of 4 patients with FECD will show moderately compromised corneal cell densities. A moderate level of damage may be optimal for clinical trials for testing topical drugs on endothelial cell viability. Thus, investigators will need to initially screen a fourfold excess of all patients with FECD.

Original languageEnglish (US)
Pages (from-to)536-539
Number of pages4
JournalEuropean Journal of Ophthalmology
Volume26
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Fuchs' Endothelial Dystrophy
Endothelial Cells
Cell Proliferation
Cell Count
Pharmaceutical Preparations
International Classification of Diseases
Clinical Trials
Data Mining
Cell Size
Glaucoma
Cataract
Cell Survival
Cross-Sectional Studies
Research Personnel
Transplants

Keywords

  • Cornea
  • Endothelium
  • FECD
  • Retrospective chart review
  • Specular photomicroscopy

ASJC Scopus subject areas

  • Medicine(all)
  • Ophthalmology

Cite this

Selecting fuchs patients for drug trials involving endothelial cell proliferation. / Shearer, Thomas (Tom); Chamberlain, Winston; Fujii, Atsuko; Azuma, Mitsuyoshi.

In: European Journal of Ophthalmology, Vol. 26, No. 6, 01.11.2016, p. 536-539.

Research output: Contribution to journalArticle

@article{e6d5ef2b361f43f5a4ed35909f77eb90,
title = "Selecting fuchs patients for drug trials involving endothelial cell proliferation",
abstract = "Purpose: Fuchs endothelial corneal dystrophy (FECD) might be managed by drug treatment before becoming severe enough to require surgery. For a clinical trial of such a drug, we hypothesize that selecting an adequate number of patients with FECD with only moderately compromised cell densities will be challenging. Thus, the purpose of the present study was to measure the prevalence of patients with FECD exhibiting moderately decreased corneal cell densities. Methods: A retrospective data mining study (cross-sectional study) was performed on patient charts presenting at a large US northwestern academic health center by searching for diagnosis ICD-9 code 371.57 and Fuchs corneal dystrophies, including those with prior cataract surgeries and/or existing glaucoma. Patients with prior corneal transplants were excluded. Noncontact specular photomicroscopic data (Topcon 2000) were obtained from the central region whenever possible, and individual eyes were grouped according to cell density (cells/mm2): severe (<800), moderate (800-1,500), and mild (>1,500). Results: The values for 98 eyes from 61 patients with FECD were as follows (mean ± SD): corneal thickness 573 ± 59 μm, cell size 627 ± 336 μm2/cell, coefficient of variation 23 ± 7, and density 1,883 ± 703 cells/mm2. The moderate subgroup with cell density values averaging 1,184 ± 212 (26) comprised 27{\%} of the total FECD patient pool. Conclusions: Only approximately 1 out of 4 patients with FECD will show moderately compromised corneal cell densities. A moderate level of damage may be optimal for clinical trials for testing topical drugs on endothelial cell viability. Thus, investigators will need to initially screen a fourfold excess of all patients with FECD.",
keywords = "Cornea, Endothelium, FECD, Retrospective chart review, Specular photomicroscopy",
author = "Shearer, {Thomas (Tom)} and Winston Chamberlain and Atsuko Fujii and Mitsuyoshi Azuma",
year = "2016",
month = "11",
day = "1",
doi = "10.5301/ejo.5000761",
language = "English (US)",
volume = "26",
pages = "536--539",
journal = "European Journal of Ophthalmology",
issn = "1120-6721",
publisher = "Wichtig Publishing",
number = "6",

}

TY - JOUR

T1 - Selecting fuchs patients for drug trials involving endothelial cell proliferation

AU - Shearer, Thomas (Tom)

AU - Chamberlain, Winston

AU - Fujii, Atsuko

AU - Azuma, Mitsuyoshi

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Purpose: Fuchs endothelial corneal dystrophy (FECD) might be managed by drug treatment before becoming severe enough to require surgery. For a clinical trial of such a drug, we hypothesize that selecting an adequate number of patients with FECD with only moderately compromised cell densities will be challenging. Thus, the purpose of the present study was to measure the prevalence of patients with FECD exhibiting moderately decreased corneal cell densities. Methods: A retrospective data mining study (cross-sectional study) was performed on patient charts presenting at a large US northwestern academic health center by searching for diagnosis ICD-9 code 371.57 and Fuchs corneal dystrophies, including those with prior cataract surgeries and/or existing glaucoma. Patients with prior corneal transplants were excluded. Noncontact specular photomicroscopic data (Topcon 2000) were obtained from the central region whenever possible, and individual eyes were grouped according to cell density (cells/mm2): severe (<800), moderate (800-1,500), and mild (>1,500). Results: The values for 98 eyes from 61 patients with FECD were as follows (mean ± SD): corneal thickness 573 ± 59 μm, cell size 627 ± 336 μm2/cell, coefficient of variation 23 ± 7, and density 1,883 ± 703 cells/mm2. The moderate subgroup with cell density values averaging 1,184 ± 212 (26) comprised 27% of the total FECD patient pool. Conclusions: Only approximately 1 out of 4 patients with FECD will show moderately compromised corneal cell densities. A moderate level of damage may be optimal for clinical trials for testing topical drugs on endothelial cell viability. Thus, investigators will need to initially screen a fourfold excess of all patients with FECD.

AB - Purpose: Fuchs endothelial corneal dystrophy (FECD) might be managed by drug treatment before becoming severe enough to require surgery. For a clinical trial of such a drug, we hypothesize that selecting an adequate number of patients with FECD with only moderately compromised cell densities will be challenging. Thus, the purpose of the present study was to measure the prevalence of patients with FECD exhibiting moderately decreased corneal cell densities. Methods: A retrospective data mining study (cross-sectional study) was performed on patient charts presenting at a large US northwestern academic health center by searching for diagnosis ICD-9 code 371.57 and Fuchs corneal dystrophies, including those with prior cataract surgeries and/or existing glaucoma. Patients with prior corneal transplants were excluded. Noncontact specular photomicroscopic data (Topcon 2000) were obtained from the central region whenever possible, and individual eyes were grouped according to cell density (cells/mm2): severe (<800), moderate (800-1,500), and mild (>1,500). Results: The values for 98 eyes from 61 patients with FECD were as follows (mean ± SD): corneal thickness 573 ± 59 μm, cell size 627 ± 336 μm2/cell, coefficient of variation 23 ± 7, and density 1,883 ± 703 cells/mm2. The moderate subgroup with cell density values averaging 1,184 ± 212 (26) comprised 27% of the total FECD patient pool. Conclusions: Only approximately 1 out of 4 patients with FECD will show moderately compromised corneal cell densities. A moderate level of damage may be optimal for clinical trials for testing topical drugs on endothelial cell viability. Thus, investigators will need to initially screen a fourfold excess of all patients with FECD.

KW - Cornea

KW - Endothelium

KW - FECD

KW - Retrospective chart review

KW - Specular photomicroscopy

UR - http://www.scopus.com/inward/record.url?scp=84994512346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994512346&partnerID=8YFLogxK

U2 - 10.5301/ejo.5000761

DO - 10.5301/ejo.5000761

M3 - Article

VL - 26

SP - 536

EP - 539

JO - European Journal of Ophthalmology

JF - European Journal of Ophthalmology

SN - 1120-6721

IS - 6

ER -